Nick Willett has received $163,000 from Absci Corporation to evaluate potential new osteoarthritis treatments. Over the next six months, Willett and co-investigators Bob Guldberg and Angela Lin will screen antibodies supplied by Absci that block inflammatory signals linked to joint damage. They’ll use the UO team’s established testing pipeline, which starts with human cartilage cells, moves to 3D lab-grown cartilage models and ends with a rat model of osteoarthritis caused by a meniscus tear. The partnership shows how Knight Campus labs can help industry speed promising therapies toward the clinic.